Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs.

Nishimuta H, Nakagawa T, Nomura N, Yabuki M.

Xenobiotica. 2013 Nov;43(11):948-55. doi: 10.3109/00498254.2013.787155. Epub 2013 Apr 17.

PMID:
23593983
2.

Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.

Nishimuta H, Sato K, Mizuki Y, Yabuki M, Komuro S.

Drug Metab Pharmacokinet. 2011 Jun;26(3):300-6. doi: 10.2133/dmpk.DMPK-10-SH-119. Epub 2011 Mar 4.

3.

Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs.

Nishimuta H, Houston JB, Galetin A.

Drug Metab Dispos. 2014 Sep;42(9):1522-31. doi: 10.1124/dmd.114.057372. Epub 2014 Jul 3.

4.

Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.

Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP.

Drug Metab Dispos. 1996 Jun;24(6):634-42.

PMID:
8781778
5.

Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs.

van Beusekom CD, Schipper L, Fink-Gremmels J.

J Vet Pharmacol Ther. 2010 Dec;33(6):519-27. doi: 10.1111/j.1365-2885.2010.01199.x. Review.

PMID:
21062303
6.

Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans.

Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S, Yamazaki H.

Arch Toxicol. 1997;71(6):401-8.

PMID:
9195021
7.

Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains.

Bruyère A, Declevès X, Bouzom F, Proust L, Martinet M, Walther B, Parmentier Y.

Xenobiotica. 2009 Jan;39(1):22-32. doi: 10.1080/00498250802517714 .

PMID:
19219745
8.
9.
10.

Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys.

Furukawa T, Naritomi Y, Tetsuka K, Nakamori F, Moriguchi H, Yamano K, Terashita S, Tabata K, Teramura T.

Xenobiotica. 2014 Mar;44(3):205-16. doi: 10.3109/00498254.2013.828362. Epub 2013 Aug 20.

PMID:
23962030
11.

Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats.

Aiba T, Takehara Y, Okuno M, Hashimoto Y.

Pharm Res. 2003 May;20(5):745-8.

PMID:
12751629
12.

In vitro cytochrome P450-mediated hepatic activities for five substrates in specific pathogen free chickens.

Khalil WF, Saitoh T, Shimoda M, Kokue E.

J Vet Pharmacol Ther. 2001 Oct;24(5):343-8. Review.

PMID:
11696084
13.

Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence.

Lin JH, Chiba M, Chen IW, Nishime JA, Vastag KJ.

Drug Metab Dispos. 1996 Dec;24(12):1298-306.

PMID:
8971134
14.

Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine.

Martignoni M, Groothuis G, de Kanter R.

Drug Metab Dispos. 2006 Jun;34(6):1047-54. Epub 2006 Mar 24.

15.

Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.

Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R.

Cancer Res. 1996 Mar 15;56(6):1296-302.

16.
17.

Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.

Cubitt HE, Houston JB, Galetin A.

Drug Metab Dispos. 2011 May;39(5):864-73. doi: 10.1124/dmd.110.036566. Epub 2011 Feb 8.

18.

Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys.

Nishimuta H, Sato K, Mizuki Y, Yabuki M, Komuro S.

Drug Metab Dispos. 2010 Nov;38(11):1967-75. doi: 10.1124/dmd.110.034561. Epub 2010 Aug 11.

19.

Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles.

Emoto C, Yoda N, Uno Y, Iwasaki K, Umehara K, Kashiyama E, Yamazaki H.

Curr Drug Metab. 2013 Feb;14(2):239-52. Review.

PMID:
22963393
20.

Supplemental Content

Support Center